Ausgabe 1/2006
Inhalt (15 Artikel)
Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment
J. H. Hooijberg, N. A. de Vries, G. J. L. Kaspers, R. Pieters, G. Jansen, G. J. Peters
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
Terzah M. Horton, Anurhadha Gannavarapu, Susan M. Blaney, David Z. D’Argenio, Sharon E. Plon, Stacey L. Berg
Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo
Lei Tao, Liang Zhou, Luying Zheng, Min Yao
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas
Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Dong Hwan Kim, Jin Ho Baek, Kyu Bo Lee, Je-Jung Lee, Ik-Joo Chung, Hyeoung-Joon Kim, Deok-Hwan Yang, Won-Sik Lee, Young-Don Joo, Chang-Hak Sohn
Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo
Chun-Bao Guo, Ying-Cun Li, Xian-Qing Jin
Human breast cell lines exhibit functional α2-adrenoceptors
Stella Maris Vázquez, Alejandro Gustavo Mladovan, Cecilia Pérez, Ariana Bruzzone, Alberto Baldi, Isabel Alicia Lüthy
Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells
Eileen Brantley, Smitha Antony, Glenda Kohlhagen, LingHua Meng, Keli Agama, Sherman F. Stinson, Edward A. Sausville, Yves Pommier
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization
William C. Rose, Punit H. Marathe, Graham R. Jang, Thomas M. Monticello, Balu N. Balasubramanian, Byron Long, Craig R. Fairchild, Monroe E. Wall, Mansukh C. Wani
Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
Kiyoshi Mori, Yukari Kamiyama, Tetsuro Kondo, Yasuhiko Kano, Tetsuro Kodama
p53 Status does not affect photodynamic cell killing induced by hypericin
H. B. Lee, A. S. H. Ho, S. H. Teo
Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein
Qiangrong Pan, Qinghua Lu, Kun Zhang, Xun Hu
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors
Joseph P. Eder Jr, David P. Ryan, Leonard Appleman, Andrew X. Zhu, Thomas Puchalski, Xiaoying He, Daryl S. Sonnichsen, Michael Cooper, John Wright, Jeffrey W. Clark, Jeffrey G. Supko
Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection
Tasha Gray, Erin L. Morrey, Bagirath Gangadharan, Takita F. Sumter, Jozef Spychala, David R. Archer, H. Trent Spencer
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme
Anne F. Schott, James M. Rae, Kent A. Griffith, Daniel F. Hayes, Vered Sterns, Laurence H. Baker
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice
Muhammad Wasif Saif, Reid von Borstel